Bortezomib (Velcade™) plus Adriamycin™ plus thalidomide plus dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM)

被引：0
|
作者：
Hollmig, K [1 ]
Stover, J [1 ]
Talamo, G [1 ]
Fassas, A [1 ]
Lee, CK [1 ]
Anaissie, E [1 ]
Tricot, G [1 ]
Barlogie, B [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2399
引用
收藏
页码：659A / 659A
页数：1
相关论文
共 50 条
  • [41] Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios A.
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw W.
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Schlossman, Robert L.
    Hou, Jian
    Moreau, Philippe
    Lonial, Sagar
    Lee, Jae Hoon
    Einsele, Hermann
    Sopala, Monika
    Bengoudifa, Bourras-Rezki
    Corrado, Claudia
    Richardson, Paul G.
    [J]. BLOOD, 2015, 126 (23)
  • [42] Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
    Palumbo, Antonio
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob P.
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Lynch, Mark
    Jou, Ying-Ming
    Jakubowiak, Andrzej
    [J]. BLOOD, 2015, 126 (23)
  • [43] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    [J]. BLOOD, 2014, 124 (21)
  • [44] Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Rosinol Dachs, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Rios, Rafael
    Hulin, Cyrille
    Jesus Blanchard, Maria
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel T.
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus F.
    Belhadj, Karim
    Jose Lahuerta, Juan
    Chen, Guang
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    Attal, Michel
    [J]. BLOOD, 2018, 132
  • [45] Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
    Palumbo, A
    Falco, P
    Ambrosini, MT
    Petrucci, MT
    Musto, P
    Caravita, T
    Pregno, P
    Bertola, A
    Cavallo, F
    Ciccone, G
    Boccadoro, M
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (05) : 391 - 395
  • [46] Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
    Jakubowiak, Andrzej
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, L. Claire
    Lynch, Mark
    Bleickardt, Eric
    Jou, Ying-Ming
    Robbins, Michael
    Palumbo, Antonio
    [J]. BLOOD, 2016, 127 (23) : 2833 - 2840
  • [47] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind phase 3 trial (vol 15, pg 1195, 2014)
    San Miguel, J. F.
    Hungria, V. T. M.
    Yoon, S-S
    [J]. LANCET ONCOLOGY, 2015, 16 (01): : E6 - E6
  • [48] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
    van Beurden-Tan, C.
    Forero, J.
    Coggia, A.
    Bustos Marquez, M. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [49] Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Punnoose, Elizabeth A.
    Cordero, Jaclyn
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed Hamed
    Freise, Kevin J.
    Leverson, Joel D.
    Enschede, Sari Heitner
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Harrison, Simon J.
    [J]. BLOOD, 2017, 130 (22) : 2392 - 2400
  • [50] Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM).
    Lacy, M.
    Gertz, M. A.
    Hayman, S. R.
    Dispenzieri, A.
    Kumar, S.
    Mikhael, J.
    Stewart, A. K.
    Allred, J.
    Mandrekar, S. J.
    Rajkumar, S. V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345